Drugs / OM-RCA-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07292168 | Dec 2025 → Jan 2027 expected | breast carcinoma, head and neck cancer, non-small cell lung carcinoma, prostate cancer +1 | Kidney Cancer Research Bureau | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OM-RCA-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07292168 ↗ |
| Action | Inhibit | “blocking the activation processes of FGFR1” NCT07292168 ↗ |
| Modality | Monoclonal antibody | “monoclonal anti-FGFR1 antibody” NCT07292168 ↗ |
| Route | Intravenous | “administered intravenously” NCT07292168 ↗ |
| Target | FGFR1 | “blocking FGFR1” NCT07292168 ↗ |